Discover the Latest in Biomedical Research Innovation

When medical residents were surveyed on interpreting a p-value, 88% were confident they understood it and 100% got it wrong. That gap is why p-value mistakes survive peer review: nobody thinks they're making one. This piece covers the five most common errors in biomedical papers, several measured at scale in real journals: the inverse probability fallacy, the replication fallacy, 'trending toward significance', p-hacking, and treating 0.05 as a bright line.

A no-fluff, step-by-step cell imaging protocol for microscopy images you can actually quantify. Eighteen numbered steps take you from Köhler setup and pixel calibration, through setting exposure on your brightest sample so nothing saturates, to acquiring the whole set under locked, identical settings. Works for brightfield, phase contrast, and fluorescence. Includes an equipment table, an acceptance-criteria checklist, and a troubleshooting table mapping each symptom to the s

Your p-value can confirm an effect is real and say nothing about whether it's big enough to matter. Effect size answers that second question, and for a two-group comparison Cohen's d is the standard measure: the mean difference divided by the pooled standard deviation. This guide covers how to calculate and report Cohen's d, why to report it alongside every p-value and confidence interval, and how to interpret it without leaning on the 0.2/0.5/0.8 benchmarks that often don't

A perfect scratch becomes unusable if the field drifts out of focus, the illumination shifts between time points, or the wound edges are too low-contrast to segment. The biggest scratch assay imaging mistakes aren't dramatic failures, they're small inconsistencies that quietly distort wound area. This guide covers the imaging principles behind reproducible wound healing assays on any microscope: imaging mode, objectives, Köhler illumination, and locking your optics.

Sophie 4.5 is live. It keeps everything that made 4.0 work and sharpens what matters: the core chat is ~40% more intelligent at the same speed, and the Regulatory Architect is 3x faster, ~25% smarter, and now wired directly into the CFR database for more accurate device classification. The Visualizer and Analytics engines get intelligence and speed bumps, and a wave of UI/UX updates came straight from how people used 4.0. Here's everything new in CLYTE's Sophie 4.5.

You asked to get CytCut onto your bench now instead of waiting, so here it is. CytCut 3.5 is available for immediate order at $36, in 24- and 48-well, the same wound healing assay tool that turns minutes of pipette scratching into seconds of consistent, reproducible wounds. It's UV- and alcohol-sanitizable with a 3–6 month working life. The autoclavable CytCut 4.0 is still on track for end of September at $99 pre-order. Order 3.5 with code cytcut352673 for $15 off through Jul

The statistics were the easy part; then you lost an afternoon nudging axis labels, adding error bars and significance stars, and redrawing schematics in Illustrator. Sophie's Visualizer, CLYTE's scientific illustration engine, lives in the same chat where you analyze your data, so you just describe the figure you want and get it publication-ready in seconds: data charts, experimental-design schematics, and mechanism diagrams. We walk through turning one finished analysis into

A former FDA reviewer ran a test for us. He took a real problem — a device with an endotoxin level his team couldn't lower — and tried to bait four AIs into approving a workaround he knew was wrong. One by one, ChatGPT, Gemini, and Claude came around and told him to proceed. Sophie refused: it cited the guidelines, held the line when he pushed, and sent him to the FDA. In regulated work, an AI eager to agree is a liability. Here's what happened — plus a test you can run yours

Stop drowning in data and start building a case. Most preclinical failures aren't technical—they're architectural. Discover why "Evidence Architecture" is the missing framework your biotech needs to survive FDA scrutiny, and hear about the rumored AI breakthrough from CLYTE that could change the game forever.

CLYTE has officially joined the Google for Startups Cloud Program, a major milestone that validates its proprietary Sophie AI technology. This partnership grants CLYTE access to Google’s advanced computational resources, accelerating the release of Sophie 3.0 in January 2026. With enhanced reliability and deep-context analysis, CLYTE is redefining lab automation. The move sets the stage for a Q1 2026 Seed Round, signaling to investors that CLYTE’s tech stack is scalable and s